House Bill 1464 creates the Mississippi “Kratom Consumer Protection Act,” a regulatory framework for the sale of kratom products in the state. The bill defines key terms such as kratom leaf, kratom leaf extract, kratom product, retailer, wholesaler, distributor, and manufacturer, and limits the definition of lawful kratom products to food or dietary supplements made from kratom leaf or extract that do not contain synthesized or semi-synthesized kratom compounds. It also sets technical composition standards, including limits on total alkaloid content and 7-hydroxymitragynine levels, and excludes products containing dangerous contaminants, controlled substances, or excessive residual solvents.
The bill imposes labeling requirements before sale, including ingredient lists, alkaloid content disclosures, manufacturer or distributor contact information, serving-size directions, allergen information, safety warnings, and a prohibition on therapeutic claims unless approved by the U.S. Food and Drug Administration. It also bars sales to persons under 21, requires kratom products to be placed behind the counter, and directs retailers to train employees on age-verification rules. Violations of the age-sale provisions are subject to a fine of $50 to $100, and retailers that properly instruct employees are shielded from liability for employee violations.
HB1464 would also require retailers, manufacturers, and wholesalers to register each kratom product intended for sale with the Mississippi Department of Revenue, pay annual registration fees, and submit certificates of analysis from U.S.-based testing facilities. Products that do not comply with the act may not be registered. In addition, processors must report adverse events involving registered kratom products to both the Department of Revenue and the FDA, and failure to report can lead to revocation of the product’s registration. The act would take effect July 1, 2025.
The overall sentiment reflected in the bill text is regulatory rather than prohibitive: it seeks to permit kratom sales while imposing consumer-protection standards, product testing, and age restrictions. Because there are no committee transcripts or recorded votes provided, there is no documented public debate or formal legislative support/opposition in the supplied materials. The bill’s structure suggests an attempt to standardize a market for kratom while addressing safety, labeling, and youth-access concerns.
The main points of potential contention are likely to be the scope of state regulation, the 21-and-over sales restriction, the registration and testing burden on businesses, and the limits on product formulation—especially the bans on synthesized or semi-synthesized alkaloids and the strict cap on 7-hydroxymitragynine. Retailers, manufacturers, and wholesalers would bear the compliance obligations, while consumers would face tighter product controls and age restrictions. The Department of Revenue would gain a new administrative role in product registration and enforcement.
HB1464 would add a new chapter of state-level regulation for kratom products in Mississippi, creating enforceable standards for product composition, labeling, testing, registration, and adverse-event reporting. It would affect retailers, wholesalers, distributors, manufacturers, and processors by requiring annual product registration with the Department of Revenue, submission of certificates of analysis, and compliance with detailed packaging and age-verification rules. It would also authorize administrative enforcement through registration denial or revocation and impose modest fines for certain violations, thereby expanding state oversight of kratom sales and distribution.
Based on the bill text alone, the measure appears to be framed as a consumer-protection and public-health regulation rather than a ban on kratom. It seeks to preserve lawful sales while imposing safety, disclosure, and youth-access controls. No committee discussion or vote history was provided, so there is no recorded evidence of legislative debate, support, or opposition in the supplied materials.
Likely areas of contention include whether kratom should be regulated at all, whether the Department of Revenue is the appropriate agency to oversee product registration, and whether the bill’s technical product standards are too restrictive for the market. Businesses may object to the cost and administrative burden of annual registration, testing, and labeling requirements, while public-health advocates may support the age limit, contamination controls, and adverse-event reporting. The prohibition on synthesized or semi-synthesized kratom compounds and the strict limits on 7-hydroxymitragynine are also likely to be debated because they could exclude certain products from the market.